Opinion: Gray-market cannabis shops open door for vape crisis 2.0
While New Yorkers sit at home and patiently wait for the adult-use market to get up and running, the gray market is flourishing.
Cannabis testing should focus on finished products and actual use
Marijuana and hemp regulatory bodies across the United States are shortsighted in their contaminant-testing requirements for cannabis and cannabis-derived products.
The expectation is that contaminants will be identified, quantified and effectively removed from the supply chain if the contamination is significant or exceeds specification levels.
FDA bans e-cigarette Juul; impact on cannabis vape market to be determined
The U.S. Food and Drug Administration ordered popular e-cigarette maker Juul’s products off the market, a move that likely won’t have an immediate impact on the marijuana vape industry but could down the road.
Pennsylvania recalls hundreds of medical marijuana vape products
Pennsylvania regulators recalled hundreds of medical marijuana vape products because the state says they contain ingredients unapproved for inhalation.
The importance of an open relationship between cannabis product manufacturers and labs
A new study of cannabis vape products from California collected during the vaping crisis of 2019 and 2020 underscored what many in the industry already know: The complexities of cannabis necessitate thorough analysis before product formulation manufacturing.
Pennsylvania’s review of vaporized medical cannabis products heats up
Controversy over a Pennsylvania review of medical marijuana vape products has mushroomed, with regulators warning that some products could be removed from the shelves, grower/processors contemplating legal action against the state and 630,000-plus patients in the dark about what to do.
Pennsylvania order targeting vaporized products upends cannabis market
In an unprecedented move, Pennsylvania medical marijuana regulators are ordering every licensed grower/processor to resubmit vaporized cannabis products that contain additives for another approval – a move that experts fear could cause serious product disruptions and financial losses.
